Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)

NCT04217356 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04217356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04217356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Patient Preferences-Controlled Study of Allogeneic Hematopoietic Cell Transplantation Versus Best Available Non-Transplant Therapies in Patients With High-Risk Myelofibrosis (ALLO-BAT Study)
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Active, not recruiting
Start date
August 5, 2020
Completion date
December 31, 2026
Enrollment
90 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bone marrow cancer, high-risk cancer, myelofibrosis